PATHOLOGIC STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Virus-Enhanced treatment shows promise for Hard-to-Treat esophageal cancer
Disease control OngoingThis early-phase trial tests a new virus-based drug (OBP-301) combined with standard chemotherapy and radiation for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The virus is designed to infect and kill cancer cells. The main goal is to check…
Matched conditions: PATHOLOGIC STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
New drug combo shows promise against esophageal cancer in early trial
Disease control OngoingThis early-phase trial is testing whether giving a mix of chemotherapy, radiation, an immunotherapy drug (pembrolizumab), and a targeted therapy (lenvatinib) before surgery can better kill esophageal cancer cells. The study includes about 3 adults with cancer that hasn't spread. …
Matched conditions: PATHOLOGIC STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC